Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G, Pei L, Xia H, Tang Q, Bi F. · 2021
Read Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. by Zhu G, Pei L, Xia H, Tang Q, Bi F. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8571891.txt.
Description
Zhu and co-authors review the oncogene KRAS in colorectal cancer prognosis, diagnosis, and treatment. Colorectal cancer varies widely at cell and molecular levels. KRAS is one of its most common mutated genes. Faults in it lock the protein on, which drives growth signals without pause.
About 40 percent of cases carry KRAS mutations, per the authors. Patients with them face a poor outlook. Testing for KRAS faults is routine before treating spread disease. KRAS was long called undruggable, a view now cracked. New inhibitors aim at the G12C form of the fault. The review weighs those drugs and the precise care this patient group needs.
Catalog record
| CREATOR | Zhu G, Pei L, Xia H, Tang Q, Bi F. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |